Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor.
In a previous study, we showed that heparitinase releases a 14-saccharide sequence (Oligo-H) from heparan sulfate (HS) with the structure delta GlcUA beta 1,4GlcNSO3-alpha 1,4[IdceA(2S)alpha 1,4GlcNSO3]5 alpha 1,4IdceA alpha 1,4GlcNAc (where IdceA(2S) represents iduronic acid 2-sulfate), which binds to basic fibroblast growth factor (bFGF) with high affinity (Turnbull, J. E., Fernig, D., Ke, Y., Wilkinson, M. C. & Gallagher, J. T. (1992) J. Biol. Chem. 267, 10337-10341). This paper describes further work on the binding properties of HS saccharides and their capacity to mediate bFGF activity in a mitogenesis assay in which responsiveness is dependent on the addition of HS or heparin. Saccharides prepared by heparinase or nitrous acid digestion and heparitinase-resistant fragments five disaccharide units (degree of polymerization (dp) = 10) or less in size were unable to activate bFGF. However, heparitinase-resistant saccharides of dp12-16 were active in the assay; the dp14 and dp16 fractions were equivalent in activity to heparin and more active than the parent HS. Saccharides of the same size and basic structure as the active fractions (> or = dp12) bound to bFGF with high relative affinity. Active saccharides were composed mainly of N-sulfated disaccharides, the predominant unit being IdceA(2S)-GlcNSO3. This was enriched at least 5-fold in the active saccharides by comparison with the original HS. In addition, the dp12 and dp14 active fractions had a notably low content of trisulfated disaccharides (IdceA(2S)-GlcNSO3(6S)) (where GlcNSO3(6S) represents N-sulfated glucosamine 6-sulfate), which are the major repeat units of heparin. The data show that sequences similar in size and basic structure to Oligo-H can mediate the mitogenic activity of bFGF. Overall, the results provide further evidence that specific HS sequences are generated biosynthetically in order to fulfill particular biological functions such as activation of bFGF.
Walker
A
A
Cancer Research Campaign Medical Oncology Department, University of Manchester, Great Britain.
Turnbull
J E
JE
Gallagher
J T
JT
D016475:3T3 Cells; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002704:Chlorates / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology*; D006497:Heparan Sulfate / Q000737:chemistry*; D051379:Mice; D008970:Molecular Weight; D009844:Oligosaccharides / Q000494:pharmacology; D011133:Polysaccharide-Lyases / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013552:Swine
D002704:Chlorates; D016222:Fibroblast Growth Factor 2; D006497:Heparan Sulfate; D009844:Oligosaccharides; D011133:Polysaccharide-Lyases; C021349:heparitinsulfate lyase